Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry.

IF 19.4 1区 医学 Q1 CRITICAL CARE MEDICINE American journal of respiratory and critical care medicine Pub Date : 2025-06-01 DOI:10.1164/rccm.202401-0023OC
Spyridon Fortis, Matthew Strand, Surya P Bhatt, Patrick Ten Eyck, Linder Wendt, Trisha Parekh, MeiLan K Han, John E Hokanson, Gregory Kinney, Jeffrey L Curtis, Russell P Bowler, Emily S Wan, Ken M Kunisaki, Chris H Wendt, Elizabeth Regan, Mark Dransfield, James D Crapo, Edwin K Silverman, Alejandro P Comellas
{"title":"Respiratory Exacerbations and Lung Function Decline in People with Smoking History and Normal Spirometry.","authors":"Spyridon Fortis, Matthew Strand, Surya P Bhatt, Patrick Ten Eyck, Linder Wendt, Trisha Parekh, MeiLan K Han, John E Hokanson, Gregory Kinney, Jeffrey L Curtis, Russell P Bowler, Emily S Wan, Ken M Kunisaki, Chris H Wendt, Elizabeth Regan, Mark Dransfield, James D Crapo, Edwin K Silverman, Alejandro P Comellas","doi":"10.1164/rccm.202401-0023OC","DOIUrl":null,"url":null,"abstract":"<p><p><b>Rationale:</b> The impact of respiratory exacerbation on chronic obstructive pulmonary disease (COPD) is well established. The effects of respiratory exacerbations in people with cigarette smoking but normal spirometry are unknown. <b>Objectives:</b> To assess the association of respiratory exacerbations with lung function decline and mortality in people with normal spirometry and current or former cigarette smoking history. <b>Methods:</b> We analyzed data from COPDGene study participants with ⩾10 pack-years of cigarette smoking and normal spirometry at enrollment (Visit 1) defined as post-bronchodilator FEV<sub>1</sub>/FVC greater than or equal to the lower limit of normal and FEV<sub>1</sub> greater than or equal to the lower limit of normal. We examined whether respiratory exacerbations occurring between Visit 1 and the 5-year follow-up visit (Visit 2) were associated with FEV<sub>1</sub> decline and all-cause mortality. <b>Measurements and Main Results:</b> Among 2,939 participants with cigarette smoking history and normal lung function at Visit 1, each additional exacerbation between Visits 1 and 2 was associated with a 2.96 ml/yr FEV<sub>1</sub> decline (95% confidence interval [CI], 1.81 to 4.12; <i>P</i> < 0.001) at Visit 2. Experiencing one or more severe exacerbations between Visits 1 and 2 was associated with 14.6 ml/yr FEV<sub>1</sub> decline relative to those with no severe exacerbations (95% CI, 8.56 to 20.6; <i>P</i> < 0.001). Individuals with one or more severe exacerbations between Visits 1 and 2 had increased mortality compared with those with no severe exacerbations (17.1% vs. 9.8%; adjusted hazard ratio, 1.97; 95% CI, 1.40 to 2.77; <i>P</i> < 0.001). <b>Conclusions:</b> Respiratory exacerbations in people with cigarette smoking but normal spirometry were associated with lung function decline. Experiencing a severe respiratory exacerbation was associated with increased mortality.</p>","PeriodicalId":7664,"journal":{"name":"American journal of respiratory and critical care medicine","volume":" ","pages":"957-965"},"PeriodicalIF":19.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12175941/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of respiratory and critical care medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1164/rccm.202401-0023OC","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CRITICAL CARE MEDICINE","Score":null,"Total":0}
引用次数: 0

Abstract

Rationale: The impact of respiratory exacerbation on chronic obstructive pulmonary disease (COPD) is well established. The effects of respiratory exacerbations in people with cigarette smoking but normal spirometry are unknown. Objectives: To assess the association of respiratory exacerbations with lung function decline and mortality in people with normal spirometry and current or former cigarette smoking history. Methods: We analyzed data from COPDGene study participants with ⩾10 pack-years of cigarette smoking and normal spirometry at enrollment (Visit 1) defined as post-bronchodilator FEV1/FVC greater than or equal to the lower limit of normal and FEV1 greater than or equal to the lower limit of normal. We examined whether respiratory exacerbations occurring between Visit 1 and the 5-year follow-up visit (Visit 2) were associated with FEV1 decline and all-cause mortality. Measurements and Main Results: Among 2,939 participants with cigarette smoking history and normal lung function at Visit 1, each additional exacerbation between Visits 1 and 2 was associated with a 2.96 ml/yr FEV1 decline (95% confidence interval [CI], 1.81 to 4.12; P < 0.001) at Visit 2. Experiencing one or more severe exacerbations between Visits 1 and 2 was associated with 14.6 ml/yr FEV1 decline relative to those with no severe exacerbations (95% CI, 8.56 to 20.6; P < 0.001). Individuals with one or more severe exacerbations between Visits 1 and 2 had increased mortality compared with those with no severe exacerbations (17.1% vs. 9.8%; adjusted hazard ratio, 1.97; 95% CI, 1.40 to 2.77; P < 0.001). Conclusions: Respiratory exacerbations in people with cigarette smoking but normal spirometry were associated with lung function decline. Experiencing a severe respiratory exacerbation was associated with increased mortality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
吸烟史和肺功能正常人群的呼吸恶化和肺功能下降。
理由:呼吸恶化对慢性阻塞性肺疾病(COPD)的影响已得到充分证实。吸烟但肺活量正常的人呼吸系统恶化的影响尚不清楚。目的:评估肺功能测定正常且有吸烟史的人群呼吸恶化与肺功能下降和死亡率的关系。方法:我们分析了COPDGene参与者的数据,这些参与者吸烟≥10包年,在入组时(访问1)肺活量正常,定义为支气管扩张剂后1秒用力呼气量(FEV1)/用力肺活量(FVC)≥正常下限(LLN)和FEV1≥LLN。我们检查了在第一次随访和5年随访(第二次随访)之间发生的呼吸恶化是否与FEV1下降和全因死亡率相关。测量和主要结果:在2939名在第一次就诊时有吸烟史且肺功能正常的参与者中,在第一次和第二次就诊之间每一次加重与2.96 ml/年FEV1下降相关(95%CI 1.81至4.12;相对于无严重恶化的患者P1下降(95% CI 8.56 ~ 20.6;结论:吸烟但肺活量正常的呼吸恶化与肺功能下降有关。经历严重的呼吸恶化与死亡率增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
27.30
自引率
4.50%
发文量
1313
审稿时长
3-6 weeks
期刊介绍: The American Journal of Respiratory and Critical Care Medicine focuses on human biology and disease, as well as animal studies that contribute to the understanding of pathophysiology and treatment of diseases that affect the respiratory system and critically ill patients. Papers that are solely or predominantly based in cell and molecular biology are published in the companion journal, the American Journal of Respiratory Cell and Molecular Biology. The Journal also seeks to publish clinical trials and outstanding review articles on areas of interest in several forms. The State-of-the-Art review is a treatise usually covering a broad field that brings bench research to the bedside. Shorter reviews are published as Critical Care Perspectives or Pulmonary Perspectives. These are generally focused on a more limited area and advance a concerted opinion about care for a specific process. Concise Clinical Reviews provide an evidence-based synthesis of the literature pertaining to topics of fundamental importance to the practice of pulmonary, critical care, and sleep medicine. Images providing advances or unusual contributions to the field are published as Images in Pulmonary, Critical Care, Sleep Medicine and the Sciences. A recent trend and future direction of the Journal has been to include debates of a topical nature on issues of importance in pulmonary and critical care medicine and to the membership of the American Thoracic Society. Other recent changes have included encompassing works from the field of critical care medicine and the extension of the editorial governing of journal policy to colleagues outside of the United States of America. The focus and direction of the Journal is to establish an international forum for state-of-the-art respiratory and critical care medicine.
期刊最新文献
Gut microbiota associate with disease severity and survival in idiopathic pulmonary fibrosis. Reply to Hong and Shu, and to Deng and Liu. Methodological Considerations for Quantitative Computed Tomography-Based Prognosis in Fibrotic Interstitial Lung Disease. Tezepelumab in Real-World U.S. Patients with Severe Asthma Across Phenotypes and Underrepresented Populations: The Phase 4 PASSAGE Study. Mechanism-Directed Pharmacotherapy in Obstructive Sleep Apnea: Insights from Aroxybutynin/Atomoxetine (AD109) Intervention in the SynAIRgy Trial.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1